TABLE 2.
Test results for determining the limits of detection of the in-house-developed nsp8 and N gene RT-LAMP-CRISPR assays and the commercial LightMix E gene RT-PCR assay with TNA extracted from Qnostics SARS-CoV-2 Q control 01a
| Concn (copies/mL) | Result |
|||||
|---|---|---|---|---|---|---|
| Intrarun |
Interrun |
|||||
| Test 1 | Test 2 | Test 3 | Test 1 | Test 2 | Test 3 | |
| nsp8 gene RT-LAMP-CRISPR assay | ||||||
| 1,000 | + | + | + | + | + | + |
| 750 | + | + | + | + | + | + |
| 500 | + | + | + | − | − | − |
| 250 | + | − | − | − | − | − |
| N gene RT-LAMP-CRISPR assay | ||||||
| 4,000 | + | + | + | + | + | + |
| 2,000 | + | + | + | + | + | + |
| 1,000 | + | + | + | + | + | − |
| 500 | − | − | − | + | + | + |
| LightMix E gene RT-PCR assay | ||||||
| 125 | + | + | + | + | + | + |
| 62.5 | + | + | + | + | + | + |
| 31.3 | + | + | + | + | + | + |
| 15.6 | + | − | − | + | + | − |
+, detected; −, not detected.